Revance Therapeutics Inc (RVNC)

[soma2022]

Daxxify dysphagia rates reported at 2.7 to 4.2%:

https://www.biospace.com/article/releases/u-s-fda-approves-first-therapeutic-indication-for-revance-s-daxxify-daxibotulinumtoxina-lanm-for-injection-for-the-treatment-of-cervical-dystonia/

Based on the ASPEN OLS study, symptoms continued to improve with successive DAXXIFY® treatments at doses up to 300U, while adverse events remained low.15-16 In particular, dysphagia rates (difficulty swallowing) remained low (2.7% for ASPEN-1 and 4.2% for ASPEN-OLS), further supporting DAXXIFY’s safety profile.15-16

Botox at 19%

https://www.botoxone.com/cervical-dystonia#:~:text=The%20most%20frequently%20reported%20adverse,%2C%20and%20headache%20(11%25).

The most frequently reported adverse reactions following injection of BOTOX for cervical dystonia include dysphagia (19%), upper respiratory infection (12%), neck pain (11%), and headache (11%).

I would expect that dysphagia rates with botox have dropped over time as technique has improved.

Revance also detailed Dysphagia rates in their presentation at the shareholder meeting last September and I believe that presentation is available on the Investor relation page of their website.